Primary Objective: To determine feasibility of telemedicine for outpatient cytokine release syndrome and neurotoxicity assessment (how many telemedicine visits successfully completed per patient)~Secondary Objective(s)~To determine how many times a telemedicine visit triggered an action (inpatient admission/ outpatient observation status)~To determine how many patients were detected to have cytokine release syndrome and/or neurotoxicity based on their telemedicine visit
The purpose of this research is to replace one of participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy follow up visits with a virtual or telemedicine visit. The telemedicine visit will use an electronic tablet with a camera and a microphone that allows participants to communicate with their physicians and nurses. Participants will be provided with the necessary equipment to complete these visits.